{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T13:31:27Z","timestamp":1777296687714,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T00:00:00Z","timestamp":1724457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81560202"],"award-info":[{"award-number":["81560202"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-70758-z","type":"journal-article","created":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:02:36Z","timestamp":1724472156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Identifying potential repurposable medications for Parkinson\u2019s disease through Mendelian randomization analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Qitong","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lifan","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benchi","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,24]]},"reference":[{"issue":"11","key":"70758_CR1","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/s1474-4422(17)30299-5","volume":"16","author":"VL Feigin","year":"2017","unstructured":"Feigin, V. L. et al. Global, regional, and national burden of neurological disorders during 1990\u20132015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 16(11), 877\u2013897. https:\/\/doi.org\/10.1016\/s1474-4422(17)30299-5 (2017).","journal-title":"Lancet Neurol."},{"issue":"5","key":"70758_CR2","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/s1474-4422(18)30499-x","volume":"18","author":"VL Feigin","year":"2019","unstructured":"Feigin, V. L. et al. Global, regional, and national burden of neurological disorders, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 18(5), 459\u2013480. https:\/\/doi.org\/10.1016\/s1474-4422(18)30499-x (2019).","journal-title":"Lancet Neurol."},{"key":"70758_CR3","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong, M. J. & Okun, M. S. Diagnosis and treatment of Parkinson disease: A review. JAMA 323, 548\u2013560. https:\/\/doi.org\/10.1001\/jama.2019.22360 (2020).","journal-title":"JAMA"},{"key":"70758_CR4","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1016\/s0140-6736(21)00218-x","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem, B. R., Okun, M. S. & Klein, C. Parkinson\u2019s disease. Lancet 397, 2284\u20132303. https:\/\/doi.org\/10.1016\/s0140-6736(21)00218-x (2021).","journal-title":"Lancet"},{"key":"70758_CR5","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/s1474-4422(22)00448-3","volume":"21","author":"JA Obeso","year":"2022","unstructured":"Obeso, J. A., Monje, M. H. G. & Matarazzo, M. Major advances in Parkinson\u2019s disease over the past two decades and future research directions. Lancet Neurol. 21, 1076\u20131079. https:\/\/doi.org\/10.1016\/s1474-4422(22)00448-3 (2022).","journal-title":"Lancet Neurol."},{"key":"70758_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrneurol.2015.236","volume":"12","author":"KR Chaudhuri","year":"2016","unstructured":"Chaudhuri, K. R. & Sauerbier, A. Parkinson disease Unravelling the nonmotor mysteries of Parkinson disease. Nat. Rev. Neurol. 12, 10\u201311. https:\/\/doi.org\/10.1038\/nrneurol.2015.236 (2016).","journal-title":"Nat. Rev. Neurol."},{"key":"70758_CR7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/s0140-6736(14)61010-2","volume":"384","author":"AH Schapira","year":"2014","unstructured":"Schapira, A. H., Olanow, C. W., Greenamyre, J. T. & Bezard, E. Slowing of neurodegeneration in Parkinson\u2019s disease and Huntington\u2019s disease: Future therapeutic perspectives. Lancet 384, 545\u2013555. https:\/\/doi.org\/10.1016\/s0140-6736(14)61010-2 (2014).","journal-title":"Lancet"},{"key":"70758_CR8","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40263-018-0548-y","volume":"32","author":"D Athauda","year":"2018","unstructured":"Athauda, D. & Foltynie, T. Drug repurposing in Parkinson\u2019s disease. CNS Drugs 32, 747\u2013761. https:\/\/doi.org\/10.1007\/s40263-018-0548-y (2018).","journal-title":"CNS Drugs"},{"key":"70758_CR9","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archneur.63.7.969","volume":"63","author":"D Weintraub","year":"2006","unstructured":"Weintraub, D. et al. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch. Neurol. 63, 969\u2013973. https:\/\/doi.org\/10.1001\/archneur.63.7.969 (2006).","journal-title":"Arch. Neurol."},{"key":"70758_CR10","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/s1474-4422(21)00249-0","volume":"20","author":"O Rascol","year":"2021","unstructured":"Rascol, O., Fabbri, M. & Poewe, W. Amantadine in the treatment of Parkinson\u2019s disease and other movement disorders. Lancet Neurol. 20, 1048\u20131056. https:\/\/doi.org\/10.1016\/s1474-4422(21)00249-0 (2021).","journal-title":"Lancet Neurol."},{"key":"70758_CR11","first-page":"668","volume":"40","author":"G DeMaagd","year":"2015","unstructured":"DeMaagd, G. & Philip, A. Parkinson\u2019s disease and its management: Part 3: Nondopaminergic and nonpharmacological treatment options. P t 40, 668\u2013679 (2015).","journal-title":"P t"},{"key":"70758_CR12","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fpsyt.2018.00091","volume":"9","author":"WY Hsu","year":"2018","unstructured":"Hsu, W. Y., Lane, H. Y. & Lin, C. H. Medications used for cognitive enhancement in patients with schizophrenia, bipolar disorder, Alzheimer\u2019s disease, and Parkinson\u2019s disease. Front. Psychiatry 9, 91. https:\/\/doi.org\/10.3389\/fpsyt.2018.00091 (2018).","journal-title":"Front. Psychiatry"},{"key":"70758_CR13","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1016\/s0140-6736(17)31585-4","volume":"390","author":"D Athauda","year":"2017","unstructured":"Athauda, D. et al. Exenatide once weekly versus placebo in Parkinson\u2019s disease: A randomised, double-blind, placebo-controlled trial. Lancet 390, 1664\u20131675. https:\/\/doi.org\/10.1016\/s0140-6736(17)31585-4 (2017).","journal-title":"Lancet"},{"key":"70758_CR14","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner, W. G. et al. Trial of lixisenatide in early Parkinson\u2019s disease. N. Engl. J. Med. 390, 1176\u20131185. https:\/\/doi.org\/10.1056\/NEJMoa2312323 (2024).","journal-title":"N. Engl. J. Med."},{"key":"70758_CR15","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","volume":"387","author":"D Devos","year":"2022","unstructured":"Devos, D. et al. Trial of deferiprone in Parkinson\u2019s disease. N. Engl. J. Med. 387, 2045\u20132055. https:\/\/doi.org\/10.1056\/NEJMoa2209254 (2022).","journal-title":"N. Engl. J. Med."},{"key":"70758_CR16","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1001\/jama.2021.10207","volume":"326","author":"MA Schwarzschild","year":"2021","unstructured":"Schwarzschild, M. A. et al. Effect of urate-elevating inosine on early Parkinson disease progression: The SURE-PD3 randomized clinical trial. JAMA 326, 926\u2013939. https:\/\/doi.org\/10.1001\/jama.2021.10207 (2021).","journal-title":"JAMA"},{"key":"70758_CR17","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamaneurol.2020.4725","volume":"78","author":"T Simuni","year":"2021","unstructured":"Simuni, T. et al. Efficacy of nilotinib in patients with moderately advanced Parkinson disease: A randomized clinical trial. JAMA Neurol. 78, 312\u2013320. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4725 (2021).","journal-title":"JAMA Neurol."},{"issue":"9","key":"70758_CR18","doi-asserted-by":"publisher","first-page":"591","DOI":"10.7326\/m19-2534","volume":"172","author":"Parkinson Study Group STEADY-PD III Investigators*","year":"2020","unstructured":"Parkinson Study Group STEADY-PD III Investigators*. Isradipine versus placebo in early Parkinson disease: A randomized trial. Ann. Intern. Med. 172(9), 591\u2013598. https:\/\/doi.org\/10.7326\/m19-2534 (2020).","journal-title":"Ann. Intern. Med."},{"key":"70758_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1001\/jamaneurol.2022.4699","volume":"80","author":"D Belete","year":"2023","unstructured":"Belete, D. et al. Association between antiepileptic drugs and incident Parkinson disease. JAMA Neurol 80, 183\u2013187. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4699 (2023).","journal-title":"JAMA Neurol"},{"key":"70758_CR20","doi-asserted-by":"publisher","first-page":"e21967","DOI":"10.1002\/syn.21967","volume":"71","author":"A Migdalska-Richards","year":"2017","unstructured":"Migdalska-Richards, A., Ko, W. K. D., Li, Q., Bezard, E. & Schapira, A. H. V. Oral ambroxol increases brain glucocerebrosidase activity in a nonhuman primate. Synapse 71, e21967. https:\/\/doi.org\/10.1002\/syn.21967 (2017).","journal-title":"Synapse"},{"key":"70758_CR21","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1186\/s12951-022-01612-5","volume":"20","author":"H Hern\u00e1ndez-Parra","year":"2022","unstructured":"Hern\u00e1ndez-Parra, H. et al. Repositioning of drugs for Parkinson\u2019s disease and pharmaceutical nanotechnology tools for their optimization. J. Nanobiotechnol. 20, 413. https:\/\/doi.org\/10.1186\/s12951-022-01612-5 (2022).","journal-title":"J. Nanobiotechnol."},{"key":"70758_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41582-019-0155-7","volume":"15","author":"A Elkouzi","year":"2019","unstructured":"Elkouzi, A., Vedam-Mai, V., Eisinger, R. S. & Okun, M. S. Emerging therapies in Parkinson disease - repurposed drugs and new approaches. Nat. Rev. Neurol. 15, 204\u2013223. https:\/\/doi.org\/10.1038\/s41582-019-0155-7 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"70758_CR23","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s43586-021-00092-5","volume":"2","author":"E Sanderson","year":"2022","unstructured":"Sanderson, E. et al. Mendelian randomization. Nat. Rev. Methods Primers 2, 6. https:\/\/doi.org\/10.1038\/s43586-021-00092-5 (2022).","journal-title":"Nat. Rev. Methods Primers"},{"key":"70758_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ije\/dyg070","volume":"32","author":"GD Smith","year":"2003","unstructured":"Smith, G. D. & Ebrahim, S. \u2018Mendelian randomization\u2019: Can genetic epidemiology contribute to understanding environmental determinants of disease?. Int. J. Epidemiol. 32, 1\u201322. https:\/\/doi.org\/10.1093\/ije\/dyg070 (2003).","journal-title":"Int. J. Epidemiol."},{"key":"70758_CR25","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/jama.2017.17219","volume":"318","author":"CA Emdin","year":"2017","unstructured":"Emdin, C. A., Khera, A. V. & Kathiresan, S. Mendelian randomization. JAMA 318, 1925\u20131926. https:\/\/doi.org\/10.1001\/jama.2017.17219 (2017).","journal-title":"JAMA"},{"key":"70758_CR26","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1038\/s41467-019-09572-5","volume":"10","author":"Y Wu","year":"2019","unstructured":"Wu, Y. et al. Genome-wide association study of medication-use and associated disease in the UK Biobank. Nat. Commun. 10, 1891. https:\/\/doi.org\/10.1038\/s41467-019-09572-5 (2019).","journal-title":"Nat. Commun."},{"key":"70758_CR27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/s1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: A meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102. https:\/\/doi.org\/10.1016\/s1474-4422(19)30320-5 (2019).","journal-title":"Lancet Neurol."},{"key":"70758_CR28","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/mds.27659","volume":"34","author":"C Blauwendraat","year":"2019","unstructured":"Blauwendraat, C. et al. Parkinson\u2019s disease age at onset genome-wide association study: Defining heritability, genetic loci, and \u03b1-synuclein mechanisms. Mov. Disord. 34, 866\u2013875. https:\/\/doi.org\/10.1002\/mds.27659 (2019).","journal-title":"Mov. Disord."},{"key":"70758_CR29","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1002\/mds.27845","volume":"34","author":"H Iwaki","year":"2019","unstructured":"Iwaki, H. et al. Genomewide association study of Parkinson\u2019s disease clinical biomarkers in 12 longitudinal patients\u2019 cohorts. Mov. Disord. 34, 1839\u20131850. https:\/\/doi.org\/10.1002\/mds.27845 (2019).","journal-title":"Mov. Disord."},{"key":"70758_CR30","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s10072-022-06494-x","volume":"44","author":"Y Zhu","year":"2023","unstructured":"Zhu, Y. et al. Assessing the association between white matter lesions and Parkinson\u2019s disease. Neurol. Sci. 44, 897\u2013903. https:\/\/doi.org\/10.1007\/s10072-022-06494-x (2023).","journal-title":"Neurol. Sci."},{"key":"70758_CR31","doi-asserted-by":"publisher","first-page":"828","DOI":"10.2337\/dc22-1385","volume":"46","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Gastrointestinal consequences of type 2 diabetes mellitus and impaired glycemic homeostasis: A Mendelian randomization study. Diabetes Care 46, 828\u2013835. https:\/\/doi.org\/10.2337\/dc22-1385 (2023).","journal-title":"Diabetes Care"},{"key":"70758_CR32","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512\u2013525. https:\/\/doi.org\/10.1093\/ije\/dyv080 (2015).","journal-title":"Int. J. Epidemiol."},{"key":"70758_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1007081","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 13, e1007081. https:\/\/doi.org\/10.1371\/journal.pgen.1007081 (2017).","journal-title":"PLoS Genet."},{"key":"70758_CR34","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1093\/brain\/awac392","volume":"146","author":"A Seyedsalehi","year":"2023","unstructured":"Seyedsalehi, A. et al. Educational attainment, structural brain reserve and Alzheimer\u2019s disease: A Mendelian randomization analysis. Brain 146, 2059\u20132074. https:\/\/doi.org\/10.1093\/brain\/awac392 (2023).","journal-title":"Brain"},{"key":"70758_CR35","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/bioinformatics\/btw373","volume":"32","author":"JR Staley","year":"2016","unstructured":"Staley, J. R. et al. PhenoScanner: A database of human genotype-phenotype associations. Bioinformatics 32, 3207\u20133209. https:\/\/doi.org\/10.1093\/bioinformatics\/btw373 (2016).","journal-title":"Bioinformatics"},{"key":"70758_CR36","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1111\/jdv.18459","volume":"36","author":"C Li","year":"2022","unstructured":"Li, C., Li, X., Lin, J., Cui, Y. & Shang, H. Psoriasis and progression of Parkinson\u2019s disease: A Mendelian randomization study. J. Eur. Acad. Dermatol. Venereol. 36, 2401\u20132405. https:\/\/doi.org\/10.1111\/jdv.18459 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"70758_CR37","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/ije\/dyt179","volume":"42","author":"MJ Brion","year":"2013","unstructured":"Brion, M. J., Shakhbazov, K. & Visscher, P. M. Calculating statistical power in Mendelian randomization studies. Int. J. Epidemiol. 42, 1497\u20131501. https:\/\/doi.org\/10.1093\/ije\/dyt179 (2013).","journal-title":"Int. J. Epidemiol."},{"key":"70758_CR38","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/aje\/kwu283","volume":"181","author":"S Burgess","year":"2015","unstructured":"Burgess, S. & Thompson, S. G. Multivariable Mendelian randomization: The use of pleiotropic genetic variants to estimate causal effects. Am. J. Epidemiol. 181, 251\u2013260. https:\/\/doi.org\/10.1093\/aje\/kwu283 (2015).","journal-title":"Am. J. Epidemiol."},{"key":"70758_CR39","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/add.15767","volume":"117","author":"J Cai","year":"2022","unstructured":"Cai, J. et al. Genetic liability for prescription opioid use and risk of cardiovascular diseases: A multivariable Mendelian randomization study. Addiction 117, 1382\u20131391. https:\/\/doi.org\/10.1111\/add.15767 (2022).","journal-title":"Addiction"},{"key":"70758_CR40","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamapsychiatry.2020.3554","volume":"78","author":"DB Rosoff","year":"2021","unstructured":"Rosoff, D. B., Smith, G. D. & Lohoff, F. W. Prescription opioid use and risk for major depressive disorder and anxiety and stress-related disorders: A multivariable Mendelian randomization analysis. JAMA Psychiatry 78, 151\u2013160. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3554 (2021).","journal-title":"JAMA Psychiatry"},{"key":"70758_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.5694\/mja2.50224","volume":"211","author":"MW Hayes","year":"2019","unstructured":"Hayes, M. W., Fung, V. S., Kimber, T. E. & O\u2019Sullivan, J. D. Updates and advances in the treatment of Parkinson disease. Med. J. Aust. 211, 277\u2013283. https:\/\/doi.org\/10.5694\/mja2.50224 (2019).","journal-title":"Med. J. Aust."},{"key":"70758_CR42","doi-asserted-by":"publisher","first-page":"e1487","DOI":"10.1212\/wnl.0000000000007173","volume":"92","author":"C Trenkwalder","year":"2019","unstructured":"Trenkwalder, C., Kuoppam\u00e4ki, M., Vahteristo, M., M\u00fcller, T. & Ellm\u00e9n, J. Increased dose of carbidopa with levodopa and entacapone improves \u201coff\u201d time in a randomized trial. Neurology 92, e1487\u2013e1496. https:\/\/doi.org\/10.1212\/wnl.0000000000007173 (2019).","journal-title":"Neurology"},{"key":"70758_CR43","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2018.02.001","volume":"51","author":"KL Chou","year":"2018","unstructured":"Chou, K. L. et al. The spectrum of \u201coff\u201d in Parkinson\u2019s disease: What have we learned over 40 years?. Parkinsonism Relat. Disord. 51, 9\u201316. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.02.001 (2018).","journal-title":"Parkinsonism Relat. Disord."},{"key":"70758_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s13311-013-0218-1","volume":"11","author":"A AlDakheel","year":"2014","unstructured":"AlDakheel, A., Kalia, L. V. & Lang, A. E. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 11, 6\u201323. https:\/\/doi.org\/10.1007\/s13311-013-0218-1 (2014).","journal-title":"Neurotherapeutics"},{"key":"70758_CR45","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamaneurol.2018.1487","volume":"75","author":"J Jankovic","year":"2018","unstructured":"Jankovic, J. et al. Safety and tolerability of multiple ascending doses of PRX002\/RG7935, an anti-\u03b1-Synuclein monoclonal antibody, in patients With Parkinson disease: A randomized clinical trial. JAMA Neurol. 75, 1206\u20131214. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1487 (2018).","journal-title":"JAMA Neurol."},{"key":"70758_CR46","doi-asserted-by":"publisher","first-page":"15017","DOI":"10.1038\/npjparkd.2015.17","volume":"1","author":"RA Barker","year":"2015","unstructured":"Barker, R. A., Studer, L., Cattaneo, E. & Takahashi, J. G-Force PD: A global initiative in coordinating stem cell-based dopamine treatments for Parkinson\u2019s disease. NPJ Parkinsons Dis. 1, 15017. https:\/\/doi.org\/10.1038\/npjparkd.2015.17 (2015).","journal-title":"NPJ Parkinsons Dis."},{"key":"70758_CR47","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1056\/NEJMoa2203395","volume":"387","author":"AE Lang","year":"2022","unstructured":"Lang, A. E. et al. Trial of Cinpanemab in early Parkinson\u2019s disease. N. Engl. J. Med. 387, 408\u2013420. https:\/\/doi.org\/10.1056\/NEJMoa2203395 (2022).","journal-title":"N. Engl. J. Med."},{"key":"70758_CR48","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano, G. et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N. Engl. J. Med. 387, 421\u2013432. https:\/\/doi.org\/10.1056\/NEJMoa2202867 (2022).","journal-title":"N. Engl. J. Med."},{"key":"70758_CR49","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: Identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov. 3, 673\u2013683. https:\/\/doi.org\/10.1038\/nrd1468 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"70758_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.healthpol.2010.12.002","volume":"100","author":"S Morgan","year":"2011","unstructured":"Morgan, S., Grootendorst, P., Lexchin, J., Cunningham, C. & Greyson, D. The cost of drug development: A systematic review. Health Policy 100, 4\u201317. https:\/\/doi.org\/10.1016\/j.healthpol.2010.12.002 (2011).","journal-title":"Health Policy"},{"key":"70758_CR51","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.drudis.2018.11.022","volume":"24","author":"P Polamreddy","year":"2019","unstructured":"Polamreddy, P. & Gattu, N. The drug repurposing landscape from 2012 to 2017: Evolution, challenges, and possible solutions. Drug Discov. Today 24, 789\u2013795. https:\/\/doi.org\/10.1016\/j.drudis.2018.11.022 (2019).","journal-title":"Drug Discov. Today"},{"key":"70758_CR52","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/cei\/uxac044","volume":"208","author":"J Xu","year":"2022","unstructured":"Xu, J. et al. Genetic correlation between thyroid hormones and Parkinson\u2019s disease. Clin. Exp. Immunol. 208, 372\u2013379. https:\/\/doi.org\/10.1093\/cei\/uxac044 (2022).","journal-title":"Clin. Exp. Immunol."},{"key":"70758_CR53","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/jpd-202265","volume":"11","author":"JH Kim","year":"2021","unstructured":"Kim, J. H. et al. Association between thyroid diseases and Parkinson\u2019s disease: A nested case-control study using a national health screening cohort. J. Parkinsons Dis. 11, 211\u2013220. https:\/\/doi.org\/10.3233\/jpd-202265 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"70758_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40618-020-01314-5","volume":"44","author":"S Mohammadi","year":"2021","unstructured":"Mohammadi, S., Dolatshahi, M. & Rahmani, F. Shedding light on thyroid hormone disorders and Parkinson disease pathology: Mechanisms and risk factors. J. Endocrinol. Invest. 44, 1\u201313. https:\/\/doi.org\/10.1007\/s40618-020-01314-5 (2021).","journal-title":"J. Endocrinol. Invest."},{"key":"70758_CR55","doi-asserted-by":"publisher","first-page":"13659","DOI":"10.1038\/s41598-019-49876-6","volume":"9","author":"EH Lee","year":"2019","unstructured":"Lee, E. H. et al. Dopamine neuron induction and the neuroprotective effects of thyroid hormone derivatives. Sci. Rep. 9, 13659. https:\/\/doi.org\/10.1038\/s41598-019-49876-6 (2019).","journal-title":"Sci. Rep."},{"key":"70758_CR56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/1098-2396(200102)39:2<167::Aid-syn8>3.0.Co;2-u","volume":"39","author":"P Teismann","year":"2001","unstructured":"Teismann, P. & Ferger, B. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson\u2019s disease. Synapse 39, 167\u2013174. https:\/\/doi.org\/10.1002\/1098-2396(200102)39:2%3c167::Aid-syn8%3e3.0.Co;2-u (2001).","journal-title":"Synapse"},{"key":"70758_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d198","volume":"342","author":"JA Driver","year":"2011","unstructured":"Driver, J. A., Logroscino, G., Lu, L., Gaziano, J. M. & Kurth, T. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson\u2019s disease: Nested case-control study. Bmj 342, d198. https:\/\/doi.org\/10.1136\/bmj.d198 (2011).","journal-title":"Bmj"},{"key":"70758_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008454.pub2","author":"K Rees","year":"2011","unstructured":"Rees, K. et al. Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson\u2019s disease: Evidence from observational studies. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD008454.pub2 (2011).","journal-title":"Cochrane Database Syst. Rev."},{"key":"70758_CR59","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41582-020-0394-7","volume":"16","author":"I Fyfe","year":"2020","unstructured":"Fyfe, I. Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease. Nat. Rev. Neurol. 16, 460. https:\/\/doi.org\/10.1038\/s41582-020-0394-7 (2020).","journal-title":"Nat. Rev. Neurol."},{"key":"70758_CR60","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1002\/mds.28189","volume":"35","author":"M San Luciano","year":"2020","unstructured":"San Luciano, M. et al. Nonsteroidal anti-inflammatory use and LRRK2 Parkinson\u2019s disease penetrance. Mov. Disord. 35, 1755\u20131764. https:\/\/doi.org\/10.1002\/mds.28189 (2020).","journal-title":"Mov. Disord."},{"key":"70758_CR61","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/j.1468-1331.2011.03399.x","volume":"18","author":"C Becker","year":"2011","unstructured":"Becker, C., Jick, S. S. & Meier, C. R. NSAID use and risk of Parkinson disease: A population-based case-control study. Eur. J. Neurol. 18, 1336\u20131342. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03399.x (2011).","journal-title":"Eur. J. Neurol."},{"key":"70758_CR62","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s1474-4422(07)70246-6","volume":"6","author":"DJ Surmeier","year":"2007","unstructured":"Surmeier, D. J. Calcium, ageing, and neuronal vulnerability in Parkinson\u2019s disease. Lancet Neurol. 6, 933\u2013938. https:\/\/doi.org\/10.1016\/s1474-4422(07)70246-6 (2007).","journal-title":"Lancet Neurol."},{"key":"70758_CR63","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1038\/nature05865","volume":"447","author":"CS Chan","year":"2007","unstructured":"Chan, C. S. et al. \u2018Rejuvenation\u2019 protects neurons in mouse models of Parkinson\u2019s disease. Nature 447, 1081\u20131086. https:\/\/doi.org\/10.1038\/nature05865 (2007).","journal-title":"Nature"},{"key":"70758_CR64","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/nature09536","volume":"468","author":"JN Guzman","year":"2010","unstructured":"Guzman, J. N. et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 468, 696\u2013700. https:\/\/doi.org\/10.1038\/nature09536 (2010).","journal-title":"Nature"},{"key":"70758_CR65","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/ncomms2149","volume":"3","author":"S Kang","year":"2012","unstructured":"Kang, S. et al. CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson\u2019s disease. Nat. Commun. 3, 1146. https:\/\/doi.org\/10.1038\/ncomms2149 (2012).","journal-title":"Nat. Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70758-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70758-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70758-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:04:14Z","timestamp":1724472254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-70758-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,24]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["70758"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-70758-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,24]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"19670"}}